Chemokine receptor CXCR2 antagonism to prevent airways inflammation

Drugs of the Future

Volumn 36, Issue 6, 2011, Pages 465-472

  Donnelly, L E ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; AZD 5069; AZD 8309; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; GLUCOCORTICOID; NAVARIXIN; PLACEBO; PREDNISOLONE; REPARIXIN; SB 265610; SB 332235; SB 455821; SB 656933; SCH 527123; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; INFECTION; NEUTROPHILIA; RESPIRATORY TRACT INFLAMMATION; REVIEW; SINGLE DRUG DOSE;

EID: 84952989976     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.06.1622072     Document Type: Review

References (97)

1. Uguccioni, M., D'Apuzzo, M., Loetscher, M., Dewald, B., Baggiolini, M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995, 25(1): 64-8.
2. Murphy, P.M., Baggiolini, M., Charo, I.F. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52(1): 145-76. (Pubitemid 30127598)
3. Baggiolini, M. Chemokines in pathology and medicine. J Intern Med 2001, 250(2): 91-104. (Pubitemid 32868689)
4. Hill, S.J. G-protein-coupled receptors: Past, present and future. Br J Pharmacol 2006, 147(S1): S27-37. (Pubitemid 43077259)
5. Proudfoot, A.E. Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2002, 2(2): 106-15. (Pubitemid 37323234)
6. Wells, T.N.C., Power, C.A., Shaw, J.P., Proudfoot, A.E.I. Chemokine blockers - Therapeutics in the making? Trends Pharmacol Sci 2006, 27(1): 41-7. (Pubitemid 43063123)
7. Murphy, P.M., Tiffany, H.L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253(5025): 1280-3. (Pubitemid 21917278)
8. Murphy, P.M. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 1997, 34(4): 311-8. (Pubitemid 27444133)
9. Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., Fine, J.S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009, 121(1): 55-68.
10. Hall, D.A., Beresford, I.J., Browning, C., Giles, H. Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: A comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol 1999, 126(3): 810-8. (Pubitemid 29087863)
11. Traves, S.L., Smith, S.J., Barnes, P.J., Donnelly, L.E. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2. J Leukoc Biol 2004, 76(2): 441-50. (Pubitemid 39006959)
12. Chuntharapai, A., Lee, J., Hebert, C.A., Kim, K.J. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol 1994, 153(12): 5682-8. (Pubitemid 24377704)
13. Stillie, R., Farooq, S.M., Gordon, J.R., Stadnyk, A.W. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 2009, 86(3): 529-43.
14. Weathington, N.M., Van Houwelingen, A.H., Noerager, B.D., Jackson, P.L., Kraneveld, A.D., Galin, F.S., Folkerts, G., Nijkamp, F.P., Blalock, J.E. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006, 12(3): 317-23. (Pubitemid 43355080)
15. Ohnishi, K., Takagi, M., Kurokawa, Y., Satomi, S., Konttinen, Y.T. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998, 78(9): 1077-87. (Pubitemid 28440824)
16. Rennard, S.I., Togo, S., Holz, O. Cigarette smoke inhibits alveolar repair: A mechanism for the development of emphysema. Proc Am Thorac Soc 2006, 3(8): 703-8. (Pubitemid 44788228)
17. Shapiro, S.D. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998, 10(5): 602-8. (Pubitemid 28477018)
18. Lee, Y.C., Lee, H.B., Rhee, Y.K., Song, C.H. The involvement of matrix metalloproteinase- 9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001, 31(10): 1623-30. (Pubitemid 32939471)
19. Matsumoto, H., Niimi, A., Takemura, M. et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005, 60(4): 277-81. (Pubitemid 40522362)
20. Vignola, A.M., Riccobono, L., Mirabella, A. et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998, 158(6): 1945-50. (Pubitemid 29008837)
21. De Kruijf, P., Lim, H.D., Overbeek, S.A. et al. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-[alpha]-PGP) does not interact directly with human CXCR1 and CXCR2. Eur J Pharmacol 2010, 643(1): 29-33.
22. Braber, S., Overbeek, S.A., Koelink, P.J. et al. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1. Eur J Pharmacol, Epub ahead of print.
23. Overbeek, S.A., Henricks, P.A.J., Srienc, A.I. et al. N-Acetylated prolineglycine-proline induced G-protein dependent chemotaxis of neutrophils is independent of CXCL8 release. Eur J Pharmacol, Epub ahead of print.
24. Snelgrove, R.J., Jackson, P.L., Hardison, M.T. et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330(6000): 90-4.
25. Barnes, P.J. Neutrophils find smoke attractive. Science 2010, 330(6000): 40-1.
26. Barnes, P.J. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007, 119(5): 1055-62. (Pubitemid 46654167)
27. Lopez, A.D., Murray, C.C. The global burden of disease, 1990-2020. Nat Med 1998, 4(11): 1241-3. (Pubitemid 28512100)
28. Barnes, P.J. Mechanisms in COPD: Differences from asthma. Chest 2000, 117(2, Suppl.): 10S-14S. (Pubitemid 30111557)
29. Stockley, R.A. Progression of chronic obstructive pulmonary disease: Impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009, 25(5): 1235-45.
30. Lindberg, A., Eriksson, B., Larsson, L.G., Ronmark, E., Sandstrom, T., Lundback, B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006, 129(4): 879-85.
31. Berry, C.E., Wise, R.A. Mortality in COPD: Causes, risk factors, and prevention. COPD 2010, 7(5): 375-82.
32. Willemse, B.W., ten Hacken, N.H., Rutgers, B., Lesman-Leegte, I.G., Postma, D.S., Timens, W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005, 26(5): 835-45. (Pubitemid 41632040)
33. Di Stefano, A., Caramori, G., Gnemmi, I. et al. Increased CCL5 and CXCL7 chemokine expression is associated with neutrophil activation in severe stable COPD. Thorax 2009, 64(11): 968-75.
34. Burnett, D., Chamba, A., Hill, S.L., Stockley, R.A. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987, 2(8567): 1043-6. (Pubitemid 17154783)
35. Sapey, E., Stockley, J.A., Greenwood, H. et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183(9): 1176-86.
36. Hamid, Q., Tulic, M. Immunobiology of asthma. Annu Rev Physiol 2009, 71(1): 489-507.
37. Hamid, Q., Tulić, M.K., Liu, M.C., Moqbel, R. Inflammatory cells in asthma: Mechanisms and implications for therapy. J Allergy Clin Immunol 2003, 111(1, Suppl. 1): S5-17.
38. Bousquet, J., Jeffery, P.K., Busse, W.W., Johnson, M., Vignola, A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161(5): 1720-45. (Pubitemid 30329053)
39. Barnes, P.J. New therapies for asthma: Is there any progress? Trends Pharmacol Sci 2010, 31(7): 335-43.
40. Hew, M., Chung, K.F. Corticosteroid insensitivity in severe asthma: Significance, mechanisms and aetiology. Intern Med J 2010, 40(5): 323-34.
41. Salvi, S., Semper, A., Blomberg, A. et al. Interleukin-5 production by human airway epithelial cells. Am J Respir Cell Mol Biol 1999, 20(5): 984-91. (Pubitemid 129540856)
42. Thomson, N.C., Chaudhuri, R., Livingston, E. Asthma and cigarette smoking. Eur Respir J 2004, 24(5): 822-33. (Pubitemid 39504438)
43. Innes, A.L., Carrington, S.D., Thornton, D.J. et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med 2009, 180(3): 203-10.
44. Pavord, I.D., Brightling, C.E., Woltmann, G., Wardlaw, A.J. Non-eosinophilic cor ticosteroid unresponsive asthma. Lancet 1999, 353(9171): 2213-4. (Pubitemid 29295261)
45. Cundall, M., Sun, Y., Miranda, C., Trudeau, J.B., Barnes, S., Wenzel, S.E. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J Allergy Clin Immunol 2003, 112(6): 1064-71. (Pubitemid 37549996)
46. Pease, J.E. Targeting chemokine receptors in allergic disease. Biochem J 2011, 434(1): 11-24.
47. Boucher, R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23(1): 146-58. (Pubitemid 38088512)
48. Downey, D.G., Bell, S.C., Elborn, J.S. Neutrophils in cystic fibrosis. Thorax 2009, 64(1): 81-8.
49. Grommes, J., Soehnlein, O. Contribution of neutrophils to acute lung injury. Mol Med 2011, 17(3-4): 293-307.
50. Tsushima, K., King, L.S., Aggarwal, N.R., De Gorordo, A., D'Alessio, F.R., Kubo, K. Acute lung injury review. Intern Med 2009, 48(9): 621-30.
51. Villard, J., Dayer-Pastore, F., Hamacher, J., Aubert, J.D., Schlegel- Haueter, S., Nicod, L.P. GRO alpha and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995, 152(5, Pt. 1): 1549-54. (Pubitemid 3002090)
52. Aggarwal, A., Baker, C.S., Evans, T.W., Haslam, P.L. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J 2000, 15(5): 895-901.
53. Kurdowska, A.N.N.A., Noble, J.M., Steinberg, K.P., Ruzinski, J.T., Hudson, L.D., Martin, T.R. Anti-interleukin 8 autoantibody:interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med 2001, 163(2): 463-8. (Pubitemid 32158529)
54. Lee, K.S., Choi, Y.H., Kim, Y.S. et al. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Respir Med 2008, 102(3): 464-9. (Pubitemid 351179973)
55. Belperio, J.A., Keane, M.P., Burdick, M.D. et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest 2002, 110(11): 1703-16. (Pubitemid 35424249)
56. Antoniou, K.M., Pataka, A., Bouros, D., Siafakas, N.M. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2007, 20(5): 453-61. (Pubitemid 47077637)
57. Koch, A.E., Polverini, P.J., Kunkel, S.L. et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258(5089): 1798-801. (Pubitemid 23087348)
58. Keane, M.P., Arenberg, D.A., Lynch, J.P. et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159(3): 1437-43. (Pubitemid 127484123)
59. Keane, M.P., Belperio, J.A., Burdick, M.D., Lynch, J.P. III, Fishbein, M.C., Strieter, R.M. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 164(12): 2239-42. (Pubitemid 34032941)
60. Ozaki, T., Hayashi, H., Tani, K., Ogushi, F., Yasuoka, S., Ogura, T. Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992, 145(1): 85-91.
61. Ziegenhagen, M.A.N.F., Zabel, P.E.T.E., Zissel, G.E.R.N., Schlaak, M.A.X., Muller-Quernheim, J.O.A.C., Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am J Respir Crit Care Med 1998, 157(3): 762-8.
62. Beeh, K.M., Beier, J., Kornmann, O., Buhl, R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(2): 138-43. (Pubitemid 36841695)
63. Hillyer, P., Mordelet, E., Flynn, G., Male, D. Chemokines, chemokine receptors and adhesion molecules on different human endothelia: Discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 2003, 134(3): 431-41. (Pubitemid 37542083)
64. Nirodi, C.S., Devalaraja, R., Nanney, L.B., Arrindell, S., Russell, S., Trupin, J., Richmond, A. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen 2000, 8(5): 371-82.
65. Sanchez, J., Moldobaeva, A., McClintock, J., Jenkins, J., Wagner, E. The role of CXCR2 in systemic neovascularization of the mouse lung. J Appl Physiol 2007, 103(2): 594-9. (Pubitemid 47204978)
66. White, J.R., Lee, J.M., Young, P.R. et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998, 273(17): 10095-8. (Pubitemid 28227606)
67. Widdowson, K.L., Elliott, J.D., Veber, D.F. et al. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 2004, 47(6): 1319-21. (Pubitemid 38327458)
68. Matzer, S.P., Zombou, J., Sarau, H.M., Röllinghoff, M., Ulrich Beuscher, H. A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 2004, 209(3): 225-33. (Pubitemid 39377858)
69. Podolin, P.L., Bolognese, B.J., Foley, J.J. et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 2002, 169(11): 6435-44. (Pubitemid 36903493)
70. Auten, R.L., Richardson, R.M., White, J.R., Mason, S.N., Vozzelli, M.A., Whorton, M.H. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. Crit Care Med 2001, 299(1): 90-5. (Pubitemid 32905122)
71. Stevenson, C.S., Coote, K., Webster, R. et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005, 288(3): L514-22. (Pubitemid 40229517)
72. Herbold, W., Maus, R., Hahn, I. et al. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect Immun 2010, 78(6): 2620-30.
73. Bradley, M.E., Bond, M.E., Manini, J., Brown, Z., Charlton, S.J. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol 2009, 158(1): 328-38.
74. Glynn, P.C., Henney, E.M., Hall, I.P. Peripheral blood neutrophils are hyperresponsive to IL-8 and Gro-alpha in cryptogenic fibrosing alveolitis. Eur Respir J 2001, 18(3): 522-9. (Pubitemid 32895638)
75. Glynn, P.C., Henney, E., Hall, I.P. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-[alpha]-mediated inhibition of spontaneous neutrophil apoptosis. Pulm Pharmacol Ther 2002, 15(2): 103-11.
76. Nicholson, G.C., Tennant, R.C., Carpenter, D.C. et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: Upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther 2007, 20(1): 52-9. (Pubitemid 44648801)
77. Dwyer, M.P., Yu, Y., Chao, J. et al. Discovery of 2-hydroxy-N,N-dimethyl- 3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino} benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem 2006, 49(26): 7603-6. (Pubitemid 46033652)
78. Chapman, R.W., Minnicozzi, M., Celly, C.S. et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007, 322(2): 486-93. (Pubitemid 47105794)
79. Gonsiorek, W., Fan, X., Hesk, D. et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007, 322(2): 477-85. (Pubitemid 47105793)
80. Baxter, A., Bennion, C., Bent, J. et al. Hit-to-lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. Bioorg Med Chem Lett 2003, 13(16): 2625-8. (Pubitemid 36851536)
81. Baxter, A., Cooper, A., Kinchin, E., Moakes, K., Unitt, J., Wallace, A. Hit-to-lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett 2006, 16(4): 960-3. (Pubitemid 43059860)
82. Walters, I., Austin, C., Austin, R. et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008, 18(2): 798-803.
83. Bertini, R., Allegretti, M., Bizzarri, C. et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004, 101(32): 11791-6. (Pubitemid 39095373)
84. Moriconi, A., Cesta, M.C., Cervellera, M.N. et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem 2007, 50(17): 3984-4002. (Pubitemid 47301732)
85. Russo, R.C., Guabiraba, R., Garcia, C.C. et al. Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2009, 40(4): 410-21.
86. Barsante, M.M., Cunha, T.M., Allegretti, M. et al. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br J Pharmacol 2008, 153(5): 992-1002. (Pubitemid 351328926)
87. Ho, K.K., Auld, D.S., Bohnstedt, A.C. et al. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett 2006, 16(10): 2724-8.
88. Jackson, P.L., Noerager, B.D., Jablonsky, M.J. et al. A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline. Eur J Pharmacol, Epub ahead of print.
89. Khalilieh, S., Tsai, M.d.V.D., Kraan, M. Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy volunteers. Eur Respir J 2007, 30(Suppl. 51): 613s.
90. Khalilieh, S., Tsai, M.v.M.S., Kraan, S. Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers. Eur Respir J 2007, 30(Suppl. 51): 612s.
91. Holz, O., Khalilieh, S., Ludwig-Sengpiel, A. et al. CH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010, 35(3): 564-70.
92. Magnussen, H., Holz, O., Watz, H. et al. Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD. Eur Respir J 2010, 36(Suppl.): 38s.
93. Gaga, M., Nair, P.K., Hargreave, F., Sadeh, J., Chanez, P. SCH527123, a novel treatment option of severe neutrophilic asthma. Am J Respir Crit Care Med 2010, 181: A6763.
94. O'Connor, B.J., Leaker, B., Barnes, P. et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur Respir J 2007, 30(Suppl. 51): 209s.
95. Lazaar, A.L., Sweeney, L.E., MacDonald, A.J., Alexis, N.E., Chen, C., Tal- Singer, R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex-vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011, Epub ahead of print.
96. Rennard, S.I., Fogarty, C., Kelsen, S.; on behalf of the COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9): 926-34. (Pubitemid 46684703)
97. Crim, C., Calverley, P.M.A., Anderson, J.A. et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34(3): 641-7.